-
Sublingual Buprenorphine-naloxone compared with injection naltrexone for opioid use disorder: Potential utility of patient characteristics in guiding choice of treatment.
Nunes EV, Scodes JM, Pavlicova M, Lee JD, Novo P, Campbell ANC, Rotrosen J. Sublingual Buprenorphine-naloxone compared with injection naltrexone for opioid use disorder: Potential utility of patient characteristics in guiding choice of treatment. American Journal of Psychiatry 2021;178(7):660-671.
-
Examination of correlates of OUD outcomes in young adults: Secondary analysis from the XBOT Trial.
Fishman M, Wenzel K, Scodes J, Pavlicova M, Campbell ANC, Rotrosen J, Nunes EV. Examination of correlates of OUD outcomes in young adults: Secondary analysis from the XBOT Trial. American Journal on Addiction 2021;30(5):433-444.
-
Care facilitation advances movement along the hepatitis C Care continuum for persons with human immunodeficiency virus, hepatitis C, and substance use: A randomized clinical trial (CTN-0064).
Metsch LR, Feaster DJ, Gooden LK, Masson C, Perlman DC, Jain MK, Matheson T, Nelson CM, Jacobs P, Tross S, Haynes L, Lucas GM, Colasanti JA, Rodriguez A, Drainoni M, Osorio G, Nijhawan AE, Jacobson JM, Sullivan M, Metzger D, Vergara-Rodriguez P, Lubelchek R, Duan R, Batycki JN, Matthews AG, Munoz F, Jelstrom E, Mandler R, Del Rio C. Care facilitation advances movement along the hepatitis C Care continuum for persons with human immunodeficiency virus, hepatitis C, and substance use: A randomized clinical trial (CTN-0064). Open Forum Infectious Diseases 2021;8(8):ofab334.
-
Participants’ treatment perspectives on a clinical trial on the use of extended-release naltrexone for substance use disorders: Considerations for future clinical research.
Bardwell G, Jaffe K, Korthuis PT, Richardson L. Participants' treatment perspectives on a clinical trial on the use of extended-release naltrexone for substance use disorders: Considerations for future clinical research. Journal of Addiction Medicine 221;15(5):390-395.
-
Association between dynamic dose increases of buprenorphine for treatment of opioid use disorder and risk of relapse.
Rudolph KA, Shulman M, Fishman MJ, Diaz I, Rotrosen J, Nunes EV. Association between dynamic dose increases of buprenorphine for treatment of opioid use disorder and risk of relapse. Addiction 2021;117(3):637-645.
-
Association between methadone or buprenorphine use during medically supervised opioid withdrawal and extended-release injectable naltrexone induction failure.
Shulman M, Choo T, Scodes J, Pavlicova M, Wai J, Haenlein P, Tofighi B, Campbell ANC, Lee JD, Rotrosen J, Nunes EV. Association between methadone or buprenorphine use during medically supervised opioid withdrawal and extended-release injectable naltrexone induction failure. Journal of Substance Abuse Treatment 2021;124:108292.
-
“This could be my last chance”: Therapeutic optimism in a randomised controlled trial for substance use disorders.
Jaffe K, Korthuis PT, Richardson L. "This could be my last chance": Therapeutic optimism in a randomised controlled trial for substance use disorders. Sociology of Health & Illness 2021; 43(5):1289-1300.
-
Baseline- and treatment-associated pain in the X:BOT comparative effectiveness study of extended-release naltrexone versus buprenorphine-naloxone for OUD.
Wang A, Shulman M, Choo T, Pavlicova M, Langleben DD, Nunes EV, Rotrosen J. Baseline- and treatment-associated pain in the X:BOT comparative effectiveness study of extended-release naltrexone versus buprenorphine-naloxone for OUD. Addiction Biology 2021:e13112.
-
The disaggregated repeated measures design: A novel approach to assess sexual risk behaviors.
Pan Y, Metsch LR, Gooden LK, Mantero AMA, Feaster DJ. The disaggregated repeated measures design: A novel approach to assess sexual risk behaviors. Archives of Sexual Behavior 2021;50(1):311-322.
-
Feasibility and acceptability of electronic administration of patient reported outcomes using mHealth platform in emergency department patients with non-medical opioid use.
Hawk K, Malicki C, Kinsman J, D'Onofrio G, Taylor A, Venkatech A. Feasibility and acceptability of electronic administration of patient reported outcomes using mHealth platform in emergency department patients with non-medical opioid use. Addiction Science & Clinical Practice 2021;16(1):66.